Table 1 Baseline cohort (n = 4001)

Age (years)at index date, median (IQR)

75 (72-79)

Follow-up time (years), mean (SD) before prostate cancer

2.9 (1.2-5.2)

Follow-up time (years), mean (SD) from prostate cancer to end of follow up

4.7 ( 2.7-7.3)

Gleason grade at presentation

Low grade

1574 (39.3%)

Intermediate

1420 (35.4%)

High grade

1007 (25.2%)

Primary treatment

Surgery

317 (7.9%)

Radiation

937 (33.2%)

Watchful waiting

1740 (43.5%)

ADT

1329 (46%)

Volume of prostate cancer

High (>30%)

2245 (56%)

Low (≤30%)

1753 (44%)

TUR diagnosis n (%)

681 (18%)

Co morbidity sum of ADGs n (%)

5 or less

1212 (30.3%)

6-9

1951 (49%)

10 or more

838 (20.7%)

*SES status n (%)

1

769 (20.3%)

2

838 (22.2%)

3

764 (20.2%)

4

693 (18.3%)

5

717 (19%)

Urban n (%)

545 (85.6%)

Prostate cancer specific death n (%)

321 (8.5%)

Overall mortality n (%)

1395 (35%)